(The Hill) — The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices.

According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products, Novo Nordisk's Wegovy and Lilly’s Zepbound, for a monthly starting price of $245 for people on Medicare and Medicaid, as well as those who use the TrumpRX platform, expected to launch early next year.

Oral GLP-1s will also be sold through the same avenues at a starting price of $149 a month. A senior administration official said, however, that this price will only apply to GLP-1 tablets that are “currently under review that will be app

See Full Page